NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,000 | -50.0% | 31 | 0.0% | 0.00% | – |
| Q1 2022 | $2,000 | -33.3% | 31 | 0.0% | 0.00% | – |
| Q4 2021 | $3,000 | -25.0% | 31 | 0.0% | 0.00% | – |
| Q3 2021 | $4,000 | -20.0% | 31 | 0.0% | 0.00% | – |
| Q2 2021 | $5,000 | -100.0% | 31 | -84.7% | 0.00% | – |
| Q1 2021 | $28,180,000 | +165664.7% | 202 | +100.0% | 0.00% | – |
| Q4 2020 | $17,000 | +21.4% | 101 | 0.0% | 0.00% | – |
| Q3 2020 | $14,000 | +7.7% | 101 | -3.8% | 0.00% | – |
| Q2 2020 | $13,000 | +30.0% | 105 | 0.0% | 0.00% | – |
| Q1 2020 | $10,000 | -16.7% | 105 | 0.0% | 0.00% | – |
| Q4 2019 | $12,000 | +33.3% | 105 | 0.0% | 0.00% | – |
| Q3 2019 | $9,000 | +125.0% | 105 | +41.9% | 0.00% | – |
| Q2 2019 | $4,000 | 0.0% | 74 | 0.0% | 0.00% | – |
| Q3 2018 | $4,000 | -33.3% | 74 | 0.0% | 0.00% | – |
| Q2 2018 | $6,000 | 0.0% | 74 | 0.0% | 0.00% | – |
| Q1 2018 | $6,000 | +50.0% | 74 | +23.3% | 0.00% | – |
| Q4 2017 | $4,000 | -20.0% | 60 | 0.0% | 0.00% | -100.0% |
| Q3 2017 | $5,000 | – | 60 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |